Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at American Society of Hematology 2022 Annual Meeting & Exposition ...Middle East

CAMBRIDGE, Mass., Dec. 10, 2022 /PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today presented new data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients...

Hence then, the article about sumitomo pharma oncology presents preliminary data from phase 1 2 clinical study evaluating investigational agent tp 3654 in patients with myelofibrosis at american society of hematology 2022 annual meeting exposition was published today ( Sunday 11/12/2022 - 02:04 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at American Society of Hematology 2022 Annual Meeting & Exposition )

Also on site :

• Firefighters fight police in France (VIDEOS)
• The NFL Names Its First-Ever 'Chief Kindness Officer' Ahead of Super Bowl LX
• 1990 Tearjerker Voted ‘Best Country Song’ of All Time